Tissue Regenix said today it expanded its operations to the US, now offering its DermaPure product for chronic and acute wound care indications in the region.
The U.K.-based company’s dCell decellularization technology is a multi-tissue regenerative medical platform designed for use in a number of applications to allow the body to regenerate critical tissue through utilizing decellularized animal and human biological material.
The DermaPure product is designed from decellularized human dermis designed fo patients with hard-to-heal acute and chronic wounds.
“We have seen first-hand how life changing these products have been in Europe, and we are thrilled to bring our dCELL Technology to the United States to help a new population of patients heal faster and more effectively. These solutions are bringing hope to people who have conditions that may otherwise be beyond repair,” CEO Antony Odell said in a press release.
The company said it expects to launch other applications of its DermaPure, including orthopedics, early next year.
“The application of dCELL Technology in orthopedics will give surgeons and clinicians an innovative new way to provide care to patients requiring anterior cruciate ligament reconstruction, meniscus replacement and other injuries,” orthopedics VP Drew Distin said in a prepared statement.